Ophthalmia neonatorum

Source: https://www.cdc.gov/

WikiDoc Resources for Ophthalmia neonatorum
Articles
Most recent articles on Ophthalmia neonatorum Most cited articles on Ophthalmia neonatorum Review articles on Ophthalmia neonatorum Articles on Ophthalmia neonatorum in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ophthalmia neonatorum Images of Ophthalmia neonatorum Photos of Ophthalmia neonatorum Podcasts & MP3s on Ophthalmia neonatorum Videos on Ophthalmia neonatorum
Evidence Based Medicine
Cochrane Collaboration on Ophthalmia neonatorum Bandolier on Ophthalmia neonatorum TRIP on Ophthalmia neonatorum
Clinical Trials
Ongoing Trials on Ophthalmia neonatorum at Clinical Trials.gov Trial results on Ophthalmia neonatorum Clinical Trials on Ophthalmia neonatorum at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ophthalmia neonatorum NICE Guidance on Ophthalmia neonatorum NHS PRODIGY Guidance FDA on Ophthalmia neonatorum CDC on Ophthalmia neonatorum
Books
Books on Ophthalmia neonatorum
News
Ophthalmia neonatorum in the news Be alerted to news on Ophthalmia neonatorum News trends on Ophthalmia neonatorum
Commentary
Blogs on Ophthalmia neonatorum
Definitions
Definitions of Ophthalmia neonatorum
Patient Resources / Community
Patient resources on Ophthalmia neonatorum Discussion groups on Ophthalmia neonatorum Patient Handouts on Ophthalmia neonatorum Directions to Hospitals Treating Ophthalmia neonatorum Risk calculators and risk factors for Ophthalmia neonatorum
Healthcare Provider Resources
Symptoms of Ophthalmia neonatorum Causes & Risk Factors for Ophthalmia neonatorum Diagnostic studies for Ophthalmia neonatorum Treatment of Ophthalmia neonatorum
Continuing Medical Education (CME)
CME Programs on Ophthalmia neonatorum
International
Ophthalmia neonatorum en Espanol Ophthalmia neonatorum en Francais
Business
Ophthalmia neonatorum in the Marketplace Patents on Ophthalmia neonatorum
Experimental / Informatics
List of terms related to Ophthalmia neonatorum

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [4]

Synonyms and keywords: Neonatal conjunctivitis

Overview

Ophthalmia neonatorum, or neonatal conjunctivitis, is a form of conjunctivitis that can be contracted by newborns during delivery. The baby can contract the disease if the eyes are contaminated during passage through the birth canal from a mother infected with either Neisseria gonorrhea, Chlamydia trachomatis, or Herpes simplex virus. It can also be caused by bacteria, viruses, and chemical irritants, such as silver nitrate, which is no longer used frequently. Ophthalmia neonatorum due to gonococci (Neisseria gonorrhoeae) typically manifests in the first 5 days of life and is associated with marked bilateral purulent discharge. In contrast, conjunctivitis secondary to infection with chlamydia (Chlamydia trachomatis) produces conjunctivitis after day 3 of life, but may occur up to 2 weeks after delivery. Babies infected with chlamydia may develop pneumonitis at a later stage (between 2 weeks and 19 weeks after delivery). Herpetic keratoconjunctivitis is a rare cause of neonatal conjunctivitis. It usually occurs within the first 2 weeks after birth. If left untreated, HSV conjunctivitis can cause corneal scarring and ulceration. Additionally, disseminated HSV infection can result in encephalitis.

Prompt diagnosis is necessary in order to establish proper treatment and minimizing potential serious complications. Common laboratory studies for neonatal conjunctivitis may include Gram stain, cultures, Giemsa stain, and polymerase chain reaction (PCR) of conjunctival scrapings. Effective measures for the prevention of ophthalmia neonatorum include ocular prophylaxis with 0.5% Erythromycin ointment or 1% Tetracycline hydrochloride, and educating pregnant women on the importance of regular examinations to detect and treat sexually transmitted infections (STIs/STDs). Empiric antibiotic treatment for neonatal conjunctivitis includes Erythromycin ophthalmic ointment and Ceftriaxone IV or IM. Additionally, systemic treatment is indicated in cases of chlamydial and Herpes simplex conjunctivitis to avoid systemic complications.

Historical Perspective

• In 1750, neonatal conjunctivitis (ophthalmia neonatorum) was first described by S.T. Quellmaz.
• In 1881, Crédé introduced 2% silver nitrate for the first time as a prophylaxis treatment method for conjunctivitis in the newborns in Leipzig.

Classification

Ophthalmia neonatorum may be classified according to etiology into 3 groups:

• Bacterial
• Viral
• Chemical

Pathophysiology

Pathogenesis

Neonatal conjunctivitis occurs in a newborn during the first month of life, and is often known as ophthalmia neonatorum. Neonatal conjunctivitis is mainly caused by sexually transmitted disease agents such as Chlamydia trachomatis, Neisseria gonorrhoeae, and herpes simplex virus (HSV). Chlamydia trachomatis is the most common cause of ophthalmia neonatorum in the developed countries because of the higher prevalence of chlamydia as a sexually transmitted disease.

The recognized routes of transmission of the organisms to the newborns include:

• Infected birth canal during vaginal birth
• Transmembrane transmission of the infection
• Transplacental transmission of the infection

Additionally, silver nitrate drops (ocular prophylaxis) can cause ocular irritation and result in chemical conjunctivitis in newborns.

Gross Pathology

On gross pathology, the following are characteristic findings of conjunctivitis:

• Conjunctival injection
• Mucopurulent discharge or non-purulent discharge
• Pseudomembrane formation
• Chemosis
• Eyelid edema

Microscopic Histopathological Analysis

On microscopic histopathological analysis, the following are characteristic findings of infective conjunctivitis in neonates:

• Mild spongiotic reaction pattern (low power view of the histology)
• Stromal infiltration by polymorphonuclear, leukocytes, plasma cells, mastocytes, and lymphocytes
• Numerous neutrophils (bacterial conjunctivitis)

Causes

Common causes include:

• Bacterial
  • Chlamydia trachomatis
  • Neisseria gonorrhoeae
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Escherichia coli
  • Klebsiella pneumoniae
  • Enterobacter
• Viral
  • Herpes simplex virus
• Aseptic
  • Chemical (silver nitrate solution)

Differentiating ophthalmia neonatorum from Other Diseases

Neonatal conjunctivitis must be differentiated from:

• Dacrocystitis
• Congenital glaucoma
• Nasolacrimal duct obstruction
• Preseptal/Orbital cellulitis
• Keratitis

Epidemiology and Demographics

Incidence

• Worldwide, ophthalmia neonatorum still blinds approximately 10,000 babies annually.

Gender

• The incidence of neonatal conjunctivitis does not varies by gender.

Developed Countries

The prevalence of neonatal conjunctivitis has decreased significantly in developed countries since the abandonment of silver nitrate as topical prophylaxis. Current prevalence of neonatal conjunctivitis in developed countries are 5 per 1,000 live births.

• In Belgium and Netherlands, the prevalence of neonatal conjunctivitis due to gonococcal infection is estimated 0.04 per 1,000 live births.
• In the United States, the prevalence of neonatal conjunctivitis due to gonococcal infection is estimated to be 0.3 per 1,000 live births.
• In the United States, the prevalence of neonatal conjunctivitis caused by chlamydial infection is estimated to be between 5-60 cases per 1,000 live births.
• In the United Kingdom, the prevalence of neonatal conjunctivitis caused by chlamydial infection is estimated to be 4 cases per 1,000 live births.

Developing Countries

• In African countries, the incidence of neonatal conjunctivitis is still high.

Risk Factors

Common risk factors in the development of neonatal conjunctivitis include:

• Maternal infections harbored in the mother's birth canal
• HIV infected mothers
• Exposure of the infant to infectious organisms
• Premature rupture of membranes (PROM)
• Inadequacy of ocular prophylaxis after birth
• Silver nitrate exposure
• Ocular trauma during delivery
• Mechanical ventilation
• Prematurity
• Poor prenatal care
• Poor hygienic delivery conditions

Screening

General screening for ophthalmia neonatorum is not recommended. However, antibiotic ointment or eye drops are given to all babies immediately after birth to prevent conjunctivitis and other medical conditions in newborns. Occasionally, this treatment causes a mild chemical conjunctivitis, which usually is self-limiting. Screening for sexually transmitted diseases in pregnant women is recommended to prevent spreading the infection to the baby in order to prevent ophthalmia neonatorum.

Organism	Screening Recommendations in Pregnant Women
Chlamydia	All pregnant women under 25 years of age Pregnant women, aged 25 and older if at increased risk Retest during the 3rd trimester for women under 25 years of age or at risk Pregnant women with chlamydial infection should have a test-of-cure 3-4 weeks after treatment and be retested within 3 months
Gonorrhea	All pregnant women under 25 years of age and older women if at increased risk Retest 3 months after treatment
Herpes simplex virus	Evidence does not support routine HSV-2 serologic screening among asymptomatic pregnant women Type-specific serologic tests might be useful for identifying pregnant women at risk for HSV infection

Natural History, Complications, and Prognosis

Natural History

Neonatal conjunctivitis is one of the most common infections occurring in the first month of life. Chemical conjunctivitis secondary to silver nitrate solution application usually occurs in the first day of life, and disappears spontaneously within 2-4 days. In the absence of adequate prophylaxis, 30%-42% of infants born by vaginal delivery to infected mothers will develop gonococcal conjunctivitis. Gonococcal conjunctivitis tends to develop between 2-7 days after birth. Gonococcal conjunctivitis typically is more severe than other causes of ophthalmia neonatorum and presents with severe bilateral purulent conjunctivitis, tearing, and eyelids swelling. If left untreated, it may cause corneal involvement such as corneal ulceration, diffuse opacification, and corneal perforation, which may to blindness, sepsis, or death. The onset of chlamydial conjunctivitis is usually later than gonococcal conjunctivitis. In the absence of adequate prophylaxis, 30%-50% of infants born by vaginal delivery to infected mothers will develop chlamydial conjunctivitis. The incubation period is 5-14 days. Chlamydial conjunctivitis presents with mild hyperemia, watery discharge, eyelid swelling, papillary reaction, and pseudomembrane formation. If left untreated, it can progress to copious and purulent discharge. This may lead to central corneal opacification and blindness. Herpetic conjunctivitis is a rare cause of neonatal conjunctivitis. It usually occurs within the first 2 weeks after birth and has an incubation period of approximately 6-14 days. If left untreated, HSV conjunctivitis can cause corneal scarring and ulceration. Additionally, disseminated HSV infection can cause central nervous system (CNS) involvement. Ophthalmia neonatorum caused by pseudomonas is rare but can present with eyelid edema, erythema, and purulent discharge. If left untreated, ophthalmia neonatorum can progress to corneal perforation, endophthalmitis, blindness, and possibly death.

Complications

Complications to neonatal conjunctivitis include:

• Ocular complications
  • Pseudomembrane formation
  • Corneal edema
  • Thickened palpebral conjunctiva
  • Peripheral pannus formation
  • Corneal opacification
  • Staphyloma
  • Corneal perforation
  • Endophthalmitis
  • Loss of eye and blindness
• Systemic complications of chlamydia conjunctivitis
  • Pneumonia
  • Otitis
  • Pharyngeal and rectal colonization
• Systemic complications of gonococcal conjunctivitis
  • Arthritis
  • Meningitis
  • Anorectal infection
  • Septicemia
• Systemic complications of herpes simplex keratoconjunctivitis
  • Encephalitis

Prognosis

Early detection and early treatment of neonatal conjunctivitis is associated with a good prognosis.

Diagnosis

Prompt diagnosis is necessary in order to establish proper treatment and minimizing potential serious complications of ophthalmia neonatorum.

History

A detailed and thorough history from the mother will help determine the prompt diagnosis and therapy. Specific areas of focus when obtaining a history from the mother include:

• History of sexually transmitted disease (STD)
• History of ocular prophylaxis with silver nitrate at the birth
• Time frame of signs and symptoms following birth

Symptoms and Physical examination

Symptoms of neonatal conjunctivitis (ophthalmia neonatorum), based on causality, may include the following:

Causality	Symptoms	Physical Examination
Gonococcal	Occurs within 2-5 days after birth Severe white bilateral discharge Tearing Eyelids swellings	Chemosis Severe lid edema Mucopurulent discharge Corneal involvement Diffuse epithelial edema, ulceration, corneal perforation, and endophthalmitis
Chlamydial	Occurs 5-14 days after birth Eye redness Watery discharge Eyelids swelling	Mild hyperemia Mucoid discharge Chemosis Pseudomembrane formation Peripheral pannus
Herpetic	Occurs within 2 weeks after birth Occurs following systemic and CNS infection Watery discharge Skin lesions on the lid margins Eye redness Eyelid edema	Nonspecific lid edema Non-mucopurulent discharge Hyperemia Vesicular lesions on the skin or lid margins
Chemical	Occurs within 24 hours of instillation of silver nitrate solution Resolves spontaneously within a few days Eyelids swelling Eye redness Tearing	Mild conjunctival injection Epiphora

Laboratory Findings

Common laboratory studies for neonatal conjunctivitis may include the following:

• Gram stain
• Cultures (blood agar, chocolate agar, or Thayer-Martin)
• Giemsa stain
• Polymerase chain reaction (PCR)

Chlamydial

• Culture of epithelial cells for obligate intracellular organisms
• Gram staining of conjunctival scrapings (neutrophils, lymphocytes, plasma cells)
• Giemsa staining of conjunctival scrapings (basophilic intracytoplasmic inclusions)
• Polymerase chain reaction (PCR) of conjunctival scrapings
• DNA hybridization assays
• Enzyme immunoassays for chlamydia organisms

Gonococcal

• Gram staining of conjunctival scrapings for (Gram-negative intra-cellular diplococci and neutrophils)
• Chocolate agar or Thayer-Martin cultures for Neisseria species

Viral

• Viral culture of corneal epithelial cells for HSV
• Direct florescent antibody (rapid detection)
• Conjunctival scrapings for polymerase chain reaction (PCR) (more sensitive than viral culture)

Imaging Findings

There are no imaging findings associated with neonatal conjunctivitis. However, CT scan and MRI may be helpful in the diagnosis of other related complication such as orbital cellulitis, meningitis, encephalitis, and pneumonia.

Treatment

Medical Treatment

• Empiric antibiotic treatment for neonatal conjunctivitis includes Erythromycin ophthalmic ointment and Ceftriaxone IV or IM - the treatment is altered when culture results are available
• Systemic treatment is necessary in cases of chlamydial conjunctivitis to eradicate the bacteria in the nasopharynx
• Prompt treatment of gonococcal conjunctivitis is essential in order to prevent the corneal ulceration
• Systemic Acyclovir is necessary in a case of HSV conjunctivitis to reduce the risk of a systemic infection
• Neonates with HSV infection require prompt consultation with the pediatrician, because systemic HSV infection can result in life-threatening condition

Infectious conjunctivitis

• 1. Common causative pathogens

• Neisseria gonorrhoeae
• Chlamydia trachomatis
• Herpes simplex virus

• 2. Conjunctivitis, neonatal prophylaxis

• Preferred regimen (1): 0.5% Erythromycin ophthalmic ointment, single dose
• Alternative regimen: 2.5% Providone-iodine solution ophthalmic ointment, single dose

• 3. Empiric antimicrobial therapy

• Preferred regimen (1): 0.5% Erythromycin ophthalmic ointment and Ceftriaxone 25-50 mg/kg (maximum dose 125 mg) IV or IM single dose

• 4. Pathogen-directed antimicrobial therapy

• 4.1 Chlamydia trachomatis

• Neonatal regimen: Erythromycin 50 mg/kg/day PO qid for 2 weeks OR Ethylsuccinate 50 mg/kg/day PO qid for 2 weeks
• Note (1): Neonates administered Erythromycin should be followed for signs and symptoms of infantile hypertrophic pyloric stenosis

• 4.2 Neisseria gonorrhoeae

• Neonatal dose: Ceftriaxone 25-50 mg/kg (maximum dose 125 mg) IV or IM, single dose

• 4.3 Herpes Simplex Virus

• Preferred regimen: Acyclovir 60 mg/kg IV tid for 2 weeks
• Alternative regimen (1): Trifluridine 1% solution q4h for 1 week
• Alternative regimen (2): Acyclovir 200 mg to 400 mg PO q5h per day for 1 week
• Alternative regimen (5): Ganciclovir 0.15% ophthlamic gel qid for 1 week
• Note (1): Prompt consultation with the pediatrician because systemic HSV infection is a life-threatening condition
• Note (2): Corticosteroids should be avoided

Chemical conjunctivitis

• Treatment of neonatal chemical conjunctivitis is not require
  • Disappears spontaneously with 2 to 3 days

Surgery

Surgical intervention is not recommended for the management of neonatal conjunctivitis (ophthalmia neonatorum).

Primary Prevention

Effective measures for the primary prevention of ophthalmia neonatorum include:

• Prophylaxis
  • Ocular prophylaxis with 0.5% erythromycin ointment or 1% tetracycline hydrochloride be given to all newborn
  • Systemic prophylaxis with ceftriaxone 50 mg/kg IM or IV, single dose is recommended in the neonate born to mothers with untreated or suspected gonococcal infection
• Educate pregnant women on the importance of regular examinations to detect and treat sexually transmitted infections (STD)
• Avoid vaginal delivery (HSV transmission rates are high for women who acquire genital herpes in the last few weeks of pregnancy)
• Avoid ocular prophylaxis with silver nitrate

Secondary Prevention

Effective measures for the secondary prevention of ophthalmia neonatorum include:

• Prompt diagnosis
• Initiate appropriate and aggressive treatment